What is KPV?

KPV is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone (alpha-MSH, residues 11-13). Alpha-MSH is a tridecapeptide derived from proopiomelanocortin with protective and anti-inflammatory effects (Brzoska 2008). KPV keeps the anti-inflammatory effect but lacks the pigmentary action of the parent hormone, which is why it has been proposed as an alternative (Brzoska 2008). This article summarises the published work and where it stops.

Mechanism

Alpha-MSH acts on melanocortin receptors, including MC-1R on monocytes, macrophages and dendritic cells, and lowers proinflammatory cytokines such as IL-1, IL-6 and TNF-alpha while raising IL-10. At the molecular level this works through inhibition of NF-kappaB activation. KPV was able to bind MC-1R and modulate antigen-presenting cell function (Luger 2003).

FindingModelSource
KPV is the C-terminal tripeptide of alpha-MSH; anti-inflammatory without pigmentary actionReviewBrzoska 2008
Alpha-MSH lowers proinflammatory cytokines, raises IL-10, inhibits NF-kappaB; KPV binds MC-1RReview of cell and mouse workLuger 2003
Systemic or topical alpha-MSH or KPV inhibited sensitization and elicitation in contact hypersensitivityMouse modelLuger 2003
Anti-inflammatory effects validated in animal models of dermatitis, vasculitis, fibrosis, arthritis, gut and airway inflammation (alpha-MSH)Animal models, reviewBrzoska 2008

Animal findings

In a mouse contact hypersensitivity model, systemic or topical alpha-MSH or KPV inhibited both the sensitization and elicitation phases, and alpha-MSH induced hapten-specific tolerance mediated by CTLA4-positive and IL-10-producing T lymphocytes (Luger 2003). The broader anti-inflammatory effects of alpha-MSH were validated in animal models of dermatitis, vasculitis, fibrosis, arthritis and inflammation in the eye, gut, brain and airways (Brzoska 2008). The reviews attribute these results mainly to alpha-MSH, with KPV proposed as the pigment-free alternative.

What the sources do not show

  • The sources checked are reviews. They do not report KPV-only dose-response data, half-life or stability figures.
  • Most animal models cited used alpha-MSH, not KPV.
  • No source checked reports a direct comparison of KPV with other tripeptides in the research formats Stackpure supplies.

Related research products and tools

Frequently Asked Questions

What is KPV?

The C-terminal tripeptide (residues 11-13) of alpha-MSH, studied for anti-inflammatory effects without the pigmentary action of the parent hormone (Brzoska 2008).

Which receptor does it use?

KPV was able to bind the melanocortin receptor MC-1R and modulate antigen-presenting cells (Luger 2003).

Is the evidence mostly on KPV?

No. Much of the animal work used alpha-MSH, and KPV is proposed as the alternative (Brzoska 2008).

Key References

  • Brzoska T, et al. Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases. Endocr Rev. 2008. PubMed 18612139
  • Luger TA, et al. New insights into the functions of alpha-MSH and related peptides in the immune system. Ann N Y Acad Sci. 2003. PubMed 12851308
  • Brzoska T, et al. Terminal signal: anti-inflammatory effects of alpha-melanocyte-stimulating hormone related peptides beyond the pharmacophore. Adv Exp Med Biol. 2010. PubMed 21222263

For research use only. Not for human consumption.